PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 14, 2016ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)218 citations

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril

View Full Paper
ADAkshay S. DesaiOVOrly VardenyBCBrian Claggett

Key Points

  • To evaluate the risk of hyperkalemia during heart failure treatment with mineralocorticoid receptor antagonists in different medication regimens.
  • Randomized trial design (NCT01035255)
  • Comparison of sacubitril/valsartan versus enalapril in heart failure patients
  • Significantly reduced risk of hyperkalemia with sacubitril/valsartan compared to enalapril, specific rates not provided.

Abstract

clinicaltrials.gov Identifier: NCT01035255.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Desai et al. (2016) studied this question.

synapsesocial.com/papers/69d861fdc025a7c015bedc33https://doi.org/10.1001/jamacardio.2016.4733
Ask AI
Helpful
Bookmark
Share
View Full Paper